MindMed has dosed the first subject in the Phase III Panorama study of MM120 ODT for the treatment of generalised anxiety ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

Kashiv Biosciences has reported that a trial of its 125mg/mL pre-filled syringe injection, KSHB002, has achieved its primary ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

The potential secretary for Health and Human Services has been forced to defend his previous anti-vaccine stances at his ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

Arena International’s Outsourcing in Clinical Trials West Coast 2025 will discuss patient centricity, diversity, and ...

Ryght AI has partnered with Cancer Research South Australia (CRSA) to advance cancer clinical trials and expand patient ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...